December #97 : WHO’s on First - by Cindra Feuer

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join

Back to home » Archives » POZ Magazine issues

Table of Contents

Born Again

Knowing When to Stop

The Divine Miss Em


Cocaine & Heroin

Crystal Meth

Harm Reduction


Recovery Rooms


A for Africa


WHO’s on First

Dying for ADAP


Bombing Gilead

Pos & Neg

Wishful Thinking

Unwrapper’s Delight

Study Hell

Tech Talk


Diarrhea Diary

HAART to Heart

Eradication II?


Breaks: What’s Up?

Safe Spliffs

Slumber Party

Bone Loss

Gimme Shelter


IRSA’s Rochelle advises HIVer refugees:

Editor's Letter


Sale of a Lifetime

Most Popular Lessons

The HIV Life Cycle


Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

email print

December 2003

WHO’s on First

by Cindra Feuer

The WHO has raised med hopes for millions. Will the WTO squash them?

Long criticized for its sleepy AIDS policy, the World Health Organization (WHO) has awakened under recently appointed Director-General Lee Jong-wook, MD. In September, WHO outlined an ambitious plan to treat three million people by 2005—insiders call it “3 by 5”—more than three times the goal of all other global programs combined. Declaring the world’s failure to bring HAART to the six million in need of a world health emergency, Lee said, “Business as usual will not work. Business as usual means watching thousands of people die every single day.”

WHO will need a breakneck stream of generic drugs to keep prices low—around $250 to $300 annually per person, experts say. That’s why, after two years of agonizing over the flexibility of international trade laws, August’s World Trade Organization (WTO) agreement on generics was widely hailed as a boon for treatment access. The WTO accord allows impoverished nations to import generics—and other countries to export them—without violating patent laws.

But activists dispute the fine print. Asia Russell of Health GAP Coalition points out that the agreement demands that exporters get additional licensing permission from patent-holders, which will slow delivery. It also forbids generic producers from using the agreement for commercial benefit. “If an Indian company exports to Zambia, and that dramatically expands the company’s market,” Russell said, “the Indian company is satisfying its commercial interests and would be forbidden to export.” Only time will tell if WHO’s renewal can ride the rulings of the WTO to save millions of lives.

[Go to top]

Facebook Twitter Google+ MySpace YouTube Tumblr Flickr Instagram
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar
POZ on Twitter

Ask POZ Pharmacist

Talk to Us
Did you participate in an event for National Black HIV/AIDS Awareness Day 2016?


more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2016 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.